Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22655945 | 0.92 | PIK3C3 (0.36) | PIK3C3PDE10ACYP17A1IDO1NPC1 | |
| SCHEMBL22655962 | 0.92 | SMN1; SMN2 (0.39) | PIK3C3PDE10ACYP17A1KDM4EHTT | |
| SCHEMBL27762686 | 0.90 | SMN1; SMN2 (0.41) | PIK3C3KDM4EHTTNPC1RAB9A | |
| SCHEMBL3737264 | 0.89 | PIK3C3 (0.36) | PIK3C3PDE10ACYP17A1IDO1 | |
| SCHEMBL25147486 | 0.87 | PIK3CA (0.38) | PIK3C3OPRL1 | |
| SCHEMBL30678855 | 0.87 | CDK9 (0.42) | NPC1RAB9A | |
| SCHEMBL31339148 | 0.87 | PIK3CA (0.38) | PIK3C3OPRL1 | |
| SCHEMBL30809349 | 0.82 | IDH1 (0.35) | PIK3C3 | |
| SCHEMBL31543568 | 0.80 | MAP3K12 (0.34) | PIK3C3 | |
| SCHEMBL28306498 | 0.79 | IDH1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105142405-A | Synergistic composition comprising a bacillus subtilis strain and a pesticide | BASF SE | 2015-12-09 | — | — | CN | claimed |
| CN-105050406-A | Composition comprising triazole compound | BASF SE | 2015-11-11 | — | — | CN | claimed |
| CN-104936450-A | Compositions comprising triazole compound | BASF SE | 2015-09-23 | — | — | CN | claimed |
| CN-104663722-A | Method for increasing the vigor and/or crop yield of agricultural plants under essentially non-existent pathogen pressure | BASF SE | 2015-06-03 | — | — | CN | claimed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024153067-A1 | HETEROCYCLE-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE, AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2010070022-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-101677540-A | Herbicidally effective composition | EIKE HUPE | 2010-03-24 | — | — | CN | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101171237-A | Process for preparing optionally 2-substituted 1, 6-dihydro-6-oxo-4-pyrimidinecarboxylic acids | DU PONT (US) | 2008-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | PIK3C3 4876/4885PDE10A 980/4885CYP17A1 4569/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | PIK3C3 240/4885PDE10A 1613/4885CYP17A1 3075/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | PIK3C3 4675/4885PDE10A 1322/4885CYP17A1 4641/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | PIK3C3 885/4885PDE10A 1754/4885CYP17A1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.